Long-term epilepsy control, motor function, cognition, sleep and quality of life in children with West syndrome

Singanamalla Bhanudeep1, Priyanka Madaan1, Naveen Sankhyan1

  • 1Pediatric Neurology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India.

Epilepsy Research
|April 16, 2021
PubMed

Insights

West syndrome (WS) outcomes at age 5+ show high rates of Lennox-Gastaut syndrome (LGS) and impaired quality of life (QoL). Early spasm onset and structural causes predict poor epilepsy outcomes.

Area of Science:

  • Pediatric Neurology
  • Developmental Neuroscience
  • Epileptology

Background:

  • West syndrome (WS) is a severe infant-onset epilepsy with significant long-term neurodevelopmental consequences.
  • Understanding long-term outcomes and predictors is crucial for early intervention and management.

Purpose of the Study:

  • To evaluate epilepsy, motor, cognitive, sleep, and quality of life (QoL) outcomes in a cohort of children with West syndrome (WS) aged 5 years and older.
  • To identify predictors of these long-term outcomes.

Main Methods:

  • A cross-sectional study of 402 children with WS (aged 5-14 years) was conducted.
  • Assessments included epilepsy severity, motor function, cognitive status, behavioral comorbidities, sleep, and QoL using standardized scales.
  • In-person and telephonic assessments were utilized.

Main Results:

  • The majority (80%) had structural etiology; 60% evolved to Lennox-Gastaut syndrome (LGS).
  • Long-term outcomes included ongoing epilepsy (65%), unfavorable motor status (32%), intellectual disability (68%), autistic spectrum disorder (26%), ADHD (11%), poor sleep (82%), and impaired QoL (70%).
  • Non-structural etiology and older age at spasm onset predicted seizure freedom.

Conclusions:

  • West syndrome frequently transitions to Lennox-Gastaut syndrome, with a high prevalence of structural etiology.
  • Early age at spasm onset (<5 months) and structural etiology are predictors of unfavorable long-term epilepsy outcomes.
  • Impaired QoL is common and correlates with cognitive, sleep, motor, and behavioral deficits.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
744
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
886
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
405
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
574
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
356